1 NAME OF THE MEDICINE
Acitretin

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each hard gelatin capsule contains 10 mg or 25 mg of acitretin as the active ingredient.

Excipients with known effect
Gelatin

For the full list of excipients see section 6.1 List of Excipients

3 PHARMACEUTICAL FORM
Novatin acitretin capsules are available in 10 and 25 mg capsules.

10 mg Capsule:
Hard gelatin capsule containing a yellow powder with a white to off-white body and a brown cap printed in black with “A10” on the capsule body.

25 mg Capsule:
Hard gelatin capsule containing a yellow powder with a yellow to light yellow body and a brown cap printed in black with “A25” on the capsule body.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS
- Severe intractable psoriasis in all its forms
- Severe forms of disorders of keratinisation such as
  - hyperkeratosis palmaris et plantaris
  - pustulosis palmaris et plantaris
  - ichthyosis
  - keratosis follicularis (Darier's disease)
  - lichen planus affecting the skin or the mucosae
  - pityriasis rubra pilaris

4.2 DOSE AND METHOD OF ADMINISTRATION
Novatin hard gelatin capsule is intended for oral administration.
Dosage

Acitretin should only be prescribed by physicians who are experienced in the use of systemic retinoids and understand the risk of teratogenicity associated with acitretin therapy.

Adults

Because there are differences in the absorption and rate of metabolism of acitretin, the dosage must be individually adjusted. The capsules should be taken preferably once daily with meals, or with milk.

An initial dosage of 25 mg or 30 mg for about two to four weeks may give satisfactory therapeutic results.

The maintenance dose must be based on clinical efficacy and tolerance. In general, a daily dosage of 25 - 50 mg taken for a further six to eight weeks achieves optimal therapeutic results.

Therapy can be terminated in patients with psoriasis whose lesions have resolved sufficiently. Relapses should be treated as described above.

In disorders of keratinisation, a continuous maintenance is mostly needed with the dose at the lowest possible level. This may be less than 20 mg and should not exceed 50 mg daily.

Children

In view of possible severe side effects associated with long-term treatment, the risk should be carefully weighed against the therapeutic benefit. Acitretin should be used only when all alternative therapies have provided inadequate. The dosage should be established on a weight basis. The daily dosage is about 0.5 mg/kg. Higher doses up to 1 mg/kg or 35 mg daily may be necessary in some cases for limited periods. Maintenance doses should be kept as low as possible in view of possible long term adverse effects.

Combined Treatment

When acitretin is used in combination with other types of therapy, it may be possible, depending on the patient's individual response, to reduce the dosage of acitretin (see section 4.5 Interactions with other medicines and other forms of interactions). Standard topical treatments can generally be continued and do not interfere with acitretin.

4.3 CONTRAINDICATIONS

Acitretin is highly teratogenic and must not be used by patients who are pregnant or who intend to become pregnant during therapy or for 2 years after cessation of therapy.

Acitretin is also contraindicated in people who are hypersensitive to acitretin or other ingredients in Acitretin or to other retinoids.

Women of childbearing potential must not receive blood from patients being treated with acitretin. Donation of blood by a patient being treated with acitretin is prohibited during and for two years after completion of treatment with acitretin.

Acitretin is contraindicated while breast feeding.

Acitretin is contraindicated in patients with severely impaired liver or kidney function and in patients with chronic abnormally elevated blood lipid values.

Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.
An increased risk of hepatitis has been reported to result from combined use of methotrexate and Tigason® (active ingredient: etretinate). Consequently, the combination of methotrexate with acitretin is also contraindicated.

Concomitant administration of acitretin and vitamin A or other retinoids is contraindicated due to the risk of hypervitaminosis A.

### 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

**Use in hepatic impairment**

Elevated transaminase and alkaline phosphatase levels have been noted in a number of patients receiving acitretin. Several cases of hepatitis have been noted in association with etretinate.

Hepatic function should be monitored before and every one to two weeks for the first two months after starting treatment with acitretin and then every three months during treatment. If pathological values for hepatic function are found, monitoring should be repeated at weekly intervals. If hepatotoxicity is suspected during acitretin treatment the drug must be discontinued and the aetiology further investigated. In such cases it is advisable to continue monitoring hepatic function for at least 3 months.

**Lipids**

Blood lipid determinations should be performed before acitretin is administered and again at intervals of one to two weeks until the lipid response to the drug is established, which is usually within four to eight weeks. Approximately 65% of patients receiving acitretin during clinical trials experienced an elevation in triglycerides. Approximately 30% developed a decrease in high density lipoproteins (HDL). The mean cholesterol level of the study population rose slightly with time but never exceeded the normal range, although some individual patients did exceed the normal range. These effects of acitretin were reversible upon cessation of therapy.

Patients with an increased tendency to develop hypertriglyceridaemia include those with diabetes mellitus, obesity, increased alcohol intake or a familial history of these conditions.

Hypertriglyceridaemia and lowered HDL may increase a patient’s cardiovascular risk status. Therefore, every attempt should be made to control significant elevations of triglycerides or HDL decreases by reduction of weight or restriction of dietary fat and alcohol intake while continuing acitretin therapy.

Serum cholesterol and serum triglycerides (fasting values) must be monitored, especially in high-risk patients (disturbances of lipid metabolism, diabetes mellitus, obesity, alcoholism) and during long-term treatment. During treatment with high doses of acitretin, reversible elevation of serum triglycerides and serum cholesterol has occurred, especially in high-risk patients (disturbances of lipid metabolism, diabetes mellitus, obesity, alcoholism). An associated risk of atherogenesis cannot be ruled out if these conditions persist.

**Use in diabetes**

In diabetics, retinoids can either improve or worsen glucose tolerance. Blood sugar levels must therefore be checked more frequently than usual in the early stages of treatment.

**Pseudotumour cerebri**

Acitretin and other retinoids administered orally have been associated with cases of pseudotumour cerebri (benign intracranial hypertension). Early signs and symptoms include papilloedema, headache, nausea and vomiting, and visual disturbances. Patients with these signs and symptoms should be examined for papilloedema and, if present, should discontinue acitretin immediately and be referred for neurologic evaluation and care.
Hyperostosis

In clinical trials with acitretin, patients were prospectively evaluated for evidence of development or change in bony abnormalities of the vertebral column. Of 262 patients treated with acitretin, 7% had pre-existing abnormalities of the spine, which showed new changes or progression of pre-existing findings. Changes included degenerative spurs, anterior bridging of spinal vertebrae, diffuse idiopathic skeletal hyperostosis, and narrowing and destruction of a cervical disc space. These existing abnormalities may be in some part attributable to the underlying psoriasis and/or the patient's age. No bone changes were seen in patients who had normal pre-treatment X-rays. A substantially higher incidence of hyperostosis has been observed with oral administration of other retinoids also involving patients without pre-existing abnormalities of the spine. Maintenance treatment may result in progression of existing spinal hyperostosis, in appearance of new hyperostotic lesions and in extraskeletal calcification, as has been observed in long-term systemic treatment with retinoids.

In adults receiving long-term treatment with acitretin, appropriate examinations should be periodically performed in view of possible ossification abnormalities (see section 4.8 Adverse effects (Undesirable effects)). If such disorders arise, the continuation of therapy should be discussed with the patient on the basis of a careful risk/benefit analysis.

General

Patients should be advised that a transient increase in psoriasis is sometimes seen during the initial treatment period.

Patients with severe headache, nausea, vomiting, and visual disturbances should discontinue acitretin immediately and be referred for neurologic evaluation and care.

Patients should be advised that they may experience decreased tolerance to contact lenses during the initial treatment period.

Donation of blood by a patient being treated with acitretin is prohibited during and for two years after completion of treatment with acitretin.

It should be emphasized that, at the present time, not all the consequences of life-long administration of acitretin are known.

For male patients treated with acitretin, available data, based on the level of maternal exposure from the semen and seminal fluid indicate a minimal, if any, risk of teratogenic effects.

Use in the elderly

No data available.

Paediatric use

Skeletal changes in premature epiphysial ossification are seen in young animals treated with etretinate. These effects have not been observed in man but only a limited number of children have been studied. Because of the uncertain effects of acitretin on growth and skeletal development, the drug should only be used in those under 18 in the following situations: life-threatening circumstances where other therapy cannot be used or is not effective; and in severe forms of the disorder for which there is no alternative therapy. Growth parameters and bone development must be closely monitored in all patients on long-term therapy, by regular measurement and X-ray.

In view of possible severe adverse effects associated with long-term treatment, the risk should be carefully weighed against the therapeutic benefit. Acitretin should be used only when alternative therapies have been exhausted.
Effects on laboratory tests

No data available.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Preliminary studies indicated that acitretin does not interfere with the actions of oestrogen-progesterone oral contraceptives. In a study of ten healthy male volunteers, acitretin did not interfere with the hypoprothrombinemic effect of the coumarin-type anticoagulant, phenprocoumon. Progestogen-only oral contraceptives (“Minipills”) should be avoided as a contraceptive measure because their efficacy may be reduced by retinoid treatment.

Concomitant administration of vitamin A and other retinoids must be avoided because of the risk of hypervitaminosis A. (see section 4.3 Contraindications).

Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type (warfarin) revealed no interaction.

Methotrexate, tetracyclines (see section 4.3 Contraindications).

In a study of twelve healthy male subjects, the concomitant administration of digoxin and acitretin did not alter the pharmacokinetics of either drug. In a study of ten healthy men, the concomitant administration of cimetidine and acitretin did not alter the pharmacokinetics of either drug.

Further interactions between acitretin and other substances (e.g. digoxin, cimetidine, combined estrogen/progestogen oral contraceptives) have not been observed so far.

In concurrent treatment with phenytoin, it must be remembered that acitretin partially reduces the protein binding of phenytoin.

Concomitant administration of alcohol may cause increased levels of etretinate, which is much slower than acitretin to be eliminated from the body. Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol. In a 2-way crossover study, all 10 subjects formed etretinate with concurrent ingestion of a single 100 mg oral dose of acitretin during a 3 hour period of ethanol ingestion (total ethanol ~1.4 g/kg body weight). A mean peak etretinate concentration of 59 ng/mL (range: 22 - 105 ng/mL) was observed and extrapolation of AUC values indicated that the formation of etretinate in this study was comparable to a single 5 mg oral dose of etretinate. Ethanol must not be ingested during treatment with acitretin by women of childbearing age, as clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol. This result was also observed in vitro. The mechanism of this metabolic process has not been defined, so it is not clear whether other interacting agents are also possible. Ethanol should be avoided for two months after cessation of acitretin therapy.

There appears to be no pharmacokinetic interaction between acitretin and cimetidine, digoxin, phenprocoumon, oral contraceptives or glyburide.
4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

No data available.

Use in pregnancy

Category X

Full patient information about the teratogenic risk and the strict pregnancy prevention measures should be given by the physician to all patients, both male and female.

Acitretin should only be prescribed by physicians who are experienced in the use of systemic retinoids and understand the risk of teratogenicity associated with acitretin therapy.

Acitretin must not be used by females who are pregnant or who may become pregnant while undergoing treatment. Acitretin is highly teratogenic. Its use is contraindicated in pregnant women and women who might become pregnant during or within 2 years of the cessation of treatment. The risk of giving birth to a deformed child is exceptionally high if acitretin is taken before or during pregnancy, no matter for how long or at what dosage. Foetal exposure to acitretin always involves a risk of congenital malformation. Acitretin has been shown to be embryotoxic and/or teratogenic in mice, rats and rabbits at doses approximately 3, 15 and 0.5 times the maximum recommended therapeutic dose, respectively.

Acitretin is contraindicated in women of childbearing potential unless the patient meets all of the following conditions:

- has severe psoriasis or disorder of keratinisation
- is unresponsive to or intolerant of standard non-teratogenic therapies
- is reliable in understanding and carrying out instructions
- is capable of complying with the mandatory contraceptive measures
- it is absolutely essential that every woman of childbearing potential who is to undergo treatment with acitretin uses effective contraception (preferably 2 complementary methods) without interruption for four weeks before, during and for 2 years after the discontinuation of treatment with acitretin. Primary contraceptive method is a combination hormonal contraceptive product or an intrauterine device and it is recommended that a condom or diaphragm (cap) is also used. Low dose progesterone-only products (minipills) are not recommended due to indications of possible interference with their contraceptive effect.
- has received both oral and written warnings of the hazards of foetal exposure to acitretin and the risk of possible contraception failure and the possible consequences if pregnancy occurs during the course of treatment with acitretin or within 2 years of discontinuing therapy and has acknowledged her understanding of these warnings.
- has had a negative serum or urine pregnancy test (minimum sensitivity of 25mlU/mL) must be obtained up to three days before the first dose is given. During therapy, pregnancy tests should be arranged at 28-day intervals. A negative pregnancy test not older than 3 days is mandatory before prescription is made at these visits. After stopping therapy, pregnancy tests should be performed at 1-3 monthly intervals for a period of 2 years after the last dose is given.
- will begin therapy only on the second or third day of the next normal menstrual period.
must avoid alcohol consumption (in food, drinks and medicine) during treatment and for 2 months after stopping treatment.

It is recommended that a prescription should not be issued until a report of a negative pregnancy test has been obtained and the patient has begun her menstrual period. It is also recommended that additional pregnancy tests are performed at monthly intervals during therapy and at 1-3 monthly intervals after stopping therapy. Acitretin is a metabolite of etretinate. Major human foetal abnormalities related to etretinate administration have been reported, including meningomyelocele, meningoencephalocele, multiple synostoses, facial dysmorphia, syndactylies, absence of terminal phalanges, malformations of hip, ankle and forearm, low set ears, high palate, decreased cranial volume, and alterations of the skull and cervical vertebrae on x-ray. Fatalities related to some of these malformations have been reported.

It is absolutely essential that every woman of childbearing potential who is to undergo treatment with acitretin uses effective contraception (preferably 2 complementary methods) must be used for at least one month before beginning acitretin therapy, throughout therapy and for two years following discontinuation of therapy. The same effective and uninterrupted contraceptive measures must be taken every time therapy is repeated, however long the intervening period may have been, and must be continued for 2 years afterwards.

The formation of etretinate has been observed in certain patients treated with acitretin. Until this phenomenon has been fully explained, the pharmacokinetic behaviour of etretinate must be taken into account. Since the elimination half-life of etretinate is approximately 120 days, contraceptive measures must be taken for two years following discontinuation of therapy even where there has been a history of infertility, unless due to hysterectomy.

Women who have taken Tigason® (etretinate) must continue to follow the contraceptive recommendations for Tigason®.

Should pregnancy occur, in spite of these precautions, there is a high risk of severe malformation of the foetus (e.g. craniofacial defects, cardiac and vascular or CNS malformations, skeletal and thymic defects) and the incidence of spontaneous abortion is increased. The risk applies especially during treatment with acitretin and 2 months after treatment. For up to 2 years after acitretin discontinuation, the risk is lower (particularly in women who have not consumed alcohol) but cannot be entirely excluded (due to possible formation of etretinate).

Use in lactation

Acitretin must not be given to nursing mothers.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Decreased night vision has been reported with acitretin therapy. Patients should be advised of this potential problem and warned to be cautious when driving or operating any vehicle at night. Visual problems should be carefully monitored.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Adverse effects are seen in most patients receiving acitretin. However, they usually disappear when the dosage is reduced or the drug withdrawn. An initial worsening of the disease symptoms is sometimes seen.

Most of the adverse effects occurring in association with systemic retinoids including acitretin resemble those of excessive vitamin A intake.

During treatment with high doses of acitretin, reversible elevation of serum triglycerides and serum cholesterol has occurred specially in high risk patients (disturbances of lipid metabolism,
diabetes mellitus, obesity, alcoholism). An associated risk of atherogenesis cannot be ruled out if these conditions persist.

**Skin and Appendages**

**Very Common**

Dry skin or lips, pruritus, erythema, rash, scaling particularly on palms and soles, skin fragility, thinning of skin, sticky skin, alopecia, nail fragility, paronychia.

**Common**

Bullous eruption, abnormal hair texture.

**Uncommon**

Photosensitivity reactions.

**Rare**

Retinoid dermatitis (occasionally provoking psoriatic lesions), urticaria.

**Frequency Not Known**

Pyogenic granuloma.

**Ocular**

**Very Common**

Dry eyes, eye irritation, intolerance of contact lenses, xerophthalmia, conjunctivitis.

**Common**

Blurred vision, impaired night vision.

**Rare**

Keratitis, corneal erosions or ulcerations, abrasion and irregularities leading to corneal opacities, papilloedema.

**Special Senses Other**

**Common**

Tinnitus, taste perversion.

**Uncommon**

Deafness.

**Respiratory**

**Common**

Drying of and inflammation of mucous membranes e.g. epistaxis, rhinitis.

**Cardiovascular**

**Common**
Flushing.

**Musculoskeletal**

**Common**

Arthralgia, arthritis, muscle, joint and bone pain. In chronic hypervitaminosis A syndrome, demineralisation and rarefaction of bone, cortical hyperostosis, periosteal calcification, premature epiphyseal closures (see section 4.4 Special warnings and precautions for use - Paediatric Use). In long-term treatment, irreversible hyperostosis and extra-skeletal calcification e.g. spinal hyperostosis and calcification of spinal ligaments resulting in spinal cord compression (see section 4.4 Special warnings and precautions for use - Hyperostosis).

**Rare**

Elevated serum creatine kinase (CK); myalgia in the case of marked CK elevation.

**Neurological and Psychiatric**

**Common**

Headache, fatigue, depression, somnolence.

**Uncommon**

Lassitude, vertigo, disturbance of consciousness, abnormal thinking, emotional lability, aggressive feelings.

**Rare**

Pseudotumour cerebri (see section 4.4 Special warnings and precautions for use - Pseudotumour Cerebri), peripheral neuropathy.

**Endocrine**

**Rare**

Gynaecomastia.

**Metabolic and nutritional**

**Very Common**

Elevated serum cholesterol and triglycerides (see section 4.4 Special warnings and precautions for use - Hepatic Toxicity).

**Rare**

Oedema, thirst.

**Liver and Biliary System**

**Very Common**

Elevated serum transaminases and alkaline phosphatase (see section 4.4 Special warnings and precautions for use - Lipids).

**Uncommon**

Jaundice, hepatitis.
Gastrointestinal
Very Common
Cheilitis, rhagades of corner of mouth, thirst, dry mouth.
Common
Stomatitis, gingivitis.
Uncommon
Gastritis, heartburn, inflammatory bowel disorders.
Rare
Pancreatitis, hepatitis, icterus.
Frequency Not Known
Dysgeusia, rectal haemorrhage.

Genitourinary
Rare
Metrorrhagia.

Immunological
Uncommon
Vulvovaginitis due to Candida albicans.

General Disorders and Administration Site Conditions
Common
Peripheral oedema.

Investigations
Very Common
Liver function test abnormal (transient, usually reversible elevation of transaminases and alkaline phosphatases. Lipids abnormal (during treatment with high doses of acitretin, reversible elevation of serum triglycerides and serum cholesterol has occurred, especially in high-risk patients and during long-term treatment. An associated risk of atherogenesis cannot be ruled out if these conditions persist).

Children
There have been occasional reports of bone changes in children, including premature epiphyseal closure, skeletal hyperostosis and extraosseous calcification after long-term treatment with etretinate, these effects may be expected with acitretin. In children, growth parameters and bone development must be closely monitored.

Diabetics
Retinoids can either improve or worsen glucose tolerance.
Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at http://www.tga.gov.au/reporting-problems and contact Apotex Medical Information Enquiries/Adverse Drug Reaction Reporting on 1800 195 055.

4.9 OVERDOSE

Symptoms
In the event of acute overdosage, acitretin must be withdrawn at once. Symptoms of overdose are identical to an acute hypervitaminosis A, i.e. headache and vertigo. The acute oral toxicity (LD₅₀) of acitretin in both mice and rats was greater than 4000 mg/kg.

Treatment
Treatment of overdose should consist of general supportive measures.

For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Mechanism of action
Acitretin reverses the epidermal proliferation and increased keratinisation seen both in chemically induced epithelial tumours in animals and in hyperkeratotic disorders in man.

Vitamin A (retinol and its esters) can beneficially influence hyperkeratotic changes in the skin or metaplasias of the mucous membranes.

Clinical trials
Use of acitretin in psoriatic patients results in improvement manifested by a decrease in scale, erythema and thickness of lesions, and decreased inflammation in the epidermis.

5.2 PHARMACOKINETIC PROPERTIES

Absorption
Acitretin reaches peak plasma concentration 1 - 5 hours after ingestion of the medicine. Bioavailability of orally administered acitretin is best when the medicine is taken together with food. Bioavailability of a single dose is approximately 60%, but this may vary considerably from one patient to another (36 - 95%).

After administration of a single 50 mg oral dose of acitretin to 18 healthy subjects, maximum plasma concentrations ranged from 196 to 728 ng/mL (mean 416 ng/mL) and were achieved in 2 to 5 hours (mean 3.5 hours). The oral absorption of acitretin is linear and proportional with increasing doses from 25 to 100 mg. Following multiple doses, acitretin plasma concentrations reached steady-state conditions within two weeks and accumulation was 0.5 to 2.6-fold higher than after a single dose. In patients with psoriasis, mean steady-state trough concentrations of acitretin increased in a proportional manner and ranged between 6 and 7 ng/mL, 11 and 14 ng/mL, and 19 and 25 ng/mL over an eight week period at daily oral doses of 10 mg, 25 mg
and 50 mg, respectively. In this same study, acitretin plasma concentrations were non-measurable (< 4-6 ng/mL) in all patients where blood samples were drawn three weeks after cessation of therapy.

**Distribution**

Acitretin is highly lipophilic and penetrates readily into body tissues. Protein binding of acitretin exceeds 99%. In animal studies, acitretin passed the placental barrier in quantities sufficient to produce foetal malformations. Due to its lipophilic nature, it can be assumed that acitretin passes into breast milk in considerable quantities.

**Metabolism**

Acitretin is metabolised by isomerisation into its 13-cis isomer (cis acitretin), by glucuronidation and cleavage of the side chain. Both acitretin and its 13-cis isomer are eliminated from the body primarily by metabolism to chain-shortened breakdown products and conjugates that are ultimately excreted in the faeces (35 - 45%) and urine (48 - 61%). The formation of the 13-cis isomer relative to parent compound is not altered by dose or fed/fasted conditions of oral administration of acitretin. The elimination of the 13-cis isomer is essentially parallel to that of acitretin after multiple doses.

There was no detectable formation of etretinate when a single 100 mg oral dose of acitretin was administered without concurrent ethanol ingestion. Although the formation of etretinate without concurrent ethanol ingestion cannot be excluded, only 7.5% of 240 evaluated psoriatic patients on acitretin therapy (5 - 60 mg/day) in controlled and uncontrolled clinical trials were found to have measurable etretinate concentrations (5 ng/mL). Of these patients, the last measurable etretinate concentration was observed at two months after cessation of acitretin therapy.

Animal studies confirm the possibility that, in the rat at least, metabolism of acitretin to etretinate in the absence of alcohol can occur.

**Excretion**

Multiple-dose studies in patients aged 21-70 years showed an elimination half-life of approximately 50 hours for acitretin and 60 hours for its main metabolite in plasma, cis acitretin, which is also a teratogen. From the longest elimination half-life observed in these patients for acitretin (96 hours) and cis acitretin (123 hours), and assuming linear kinetics, it can be predicted that more than 99% of the drug is eliminated within 36 days after cessation of long-term therapy. Furthermore, plasma concentrations of acitretin and cis acitretin dropped below the sensitivity limit of the assay (< 6 ng/mL) within 36 days following cessation of treatment. Acitretin is excreted entirely in the form of its metabolites, in approximately equal parts via the kidneys and the bile.

**Special Populations**

Plasma concentrations of acitretin were significantly lower in end stage renal failure subjects (n = 6) when compared to age-matched controls following single 50 mg oral doses. However, acitretin was not removed by haemodialysis in these subjects.

In a multiple-dose study in healthy young (n = 6) and elderly (n = 8) subjects, increased acitretin plasma concentrations were seen in elderly subjects although the elimination half-life did not change.

**NOTE:**

In a study with healthy volunteers, concurrent intake of a single dose of acitretin together with ethanol led to the formation of etretinate. This was already observed *in vitro*. In recent investigations, the formation of etretinate has also been observed in certain patients treated...
with acitretin. Until this phenomenon has been fully explained, the pharmacokinetic behaviour of etretinate must be taken into account. Therefore, since the elimination half-life of etretinate is approximately 120 days, contraceptive measures must be taken for 2 years after completion of acitretin treatment.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity
No data available.

Carcinogenicity
Carcinogenicity studies carried out with acitretin showed an increase in the frequency of blood vessel tumours (haemangiomas and haemangiosarcomas) in male mice.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

- Maltodextrin
- sodium ascorbate
- microcrystalline cellulose
- gelatin
- sodium lauryl sulfate
- purified water
- shellac glaze
- iron oxide black (E172),
- propylene glycol (E1520))
- iron oxide red (E172)
- iron oxide yellow (E172)
- titanium dioxide

6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 25°C. Protect from light and moisture.

The product is sensitive to moisture, therefore, store in the original package.
6.5 NATURE AND CONTENTS OF CONTAINER

10 mg Capsule:
Blister pack (PVC/PVDC/Aluminium foil) of 60 and 100 capsules (AUST R 196006)

25 mg Capsule:
Blister pack (PVC/PVDC/Aluminium foil) of 60 and 100 capsules (AUST R 196003)
Not all strengths and/or pack sizes may be available.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES

NOVATIN (acitretin) is a retinoid for the oral treatment of severe cases of psoriasis and disorders of keratinisation.

Acitretin is a metabolite of etretinate and is related to both retinoic acid and retinol (Vitamin A).
Acitretin is a green-yellow crystalline powder. It is virtually insoluble in water (< 0.1 mg/100 mL). The pKa is approximately 5. It is present in the capsules as a spray-dried powder.

Chemical structure

Chemical name: 2E,4E,6E,8E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
Molecular Formula: C_{21}H_{26}O_{3}
Molecular Weight: 326.44

CAS number
55079-83-9

7 MEDICINE SCHEDULE (POISONS STANDARD)
S4 – Prescription Only Medicine

8 SPONSOR
Apotex Pty Ltd
16 Giffnock Avenue
Macquarie Park NSW 2113

Tel: (02) 8877 8333
Web: www1.apotex.com/au
9 DATE OF FIRST APPROVAL
23 May 2013

10 DATE OF REVISION
27 November 2018

Summary table of changes

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>Reformatted product information; minor editorial changes</td>
</tr>
</tbody>
</table>
